On July 16, 2020, Marx, Matthew Arnold; Christensen, James Gail; Smith, Christopher Randolph; Fischer, John P.; Burns, Aaron Craig published a patent.Recommanded Product: 58142-46-4 The title of the patent was Preparation of pyrimidine derivatives as KRas G12C inhibitors for the treatment of KRas-mediated diseases. And the patent contained the following:
The invention relates to preparation of pyrimidines(I) that inhibit KRas G12C. Compounds I wherein X is a 4-12 membered saturated or partially saturated monocyclic, bridged, spirocyclic or fused bicyclic ring; Y is a bond, O, S, etc.; R2 is H, alkyl, alkoxy, etc.; L is bond, C(O), or C1-3 alkylene; R4 is H, aryl, cycloalkyl, etc.; etc., are claimed. The example compound II was prepared via multi-steps synthesis using 4,7-dichloropyrido[4,3-d]pyrimidine as starting material (procedure given). Compounds I are irreversible inhibitors of of KRas G12C (data given). Compounds I can be used in treatment of diseases that are KRas-mediated as well as caused by KRas G12C mutation. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 58142-46-4
The Article related to pyrimidine preparation kras g12c inhibitor disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 58142-46-4
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem